Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05795348
Other study ID # ForceLoss II
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 28, 2023
Est. completion date May 27, 2024

Study information

Verified date May 2024
Source Istituto Ortopedico Rizzoli
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ForceLoss study aims to develop personalised modeling and simulation procedures to enable the differential diagnosis for the loss of muscle force, namely dynapenia. The primary causes of dynapenia can be identified in a diffuse or selective sarcopenia, a lack of activation (inhibition), or suboptimal motor control. Each of these causes requires different interventions, but a reliable differential diagnosis is currently impossible. While biomedical instruments and tools can provide valuable information, it is often left to the experience of the single clinican to integrate such information into a complete diagnostic picture. An accurate diagnosis for dynapenia is important for a number of pathologies, including neurological diseases, age-related frailty, diabetes, and orthopaedic conditions. The hypothesis is that the use of mechanistic, subject-specific models (digital twins) to simulate a maximal isometric knee extension task, informed by experimental measures may be employed to conduct a robust differential diagnosis for dynapenia. In this study, on patients candidate for knee arthroplasty, the investigators will expand (i) the experimental protocol previously developed and tested on healthy volunteers with a measure of involuntary muscle contraction (superimposed neuromuscular electrical stimulation, SNMES), a hand-grip test, measures of bio-impedance and clinical questionnaires, and (ii) the modeling and simulation framework to include one additional step (to check for muscle inhibition). Medical imaging, electromyography (EMG) and dynamometry data will be collected and combined to inform a digital twin of each participant. Biomechanical computer simulations of a Maximal Voluntary Isometric Contraction (MVIC) task will then be performed. Comparing the models' estimates to in vivo dynamometry measurements and EMG data, the investigators will test one by one the three possible causes of dynapenia, and, through a process of hypothesis falsification will exclude those that do not explain the observed loss of muscle force.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 27, 2024
Est. primary completion date May 27, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of Primary Arthrosis at the knee (according to the American College of Rheumatology criteria), subjects elected for tota knee arthroplasty - Body Mass Index between 18.5 and 30 kg/m2 - Health status (according to the American Society of Anesthesiology classification) equal to 1 or 2 - Suspected systemic sarcopenia due to aging or localized sarcopenia due to disuse Exclusion Criteria: - Neurological, rheumatic or tumoral diseases - Inguinal or abdominal hernia - Diabetes - Severe Hypertension (Level 3) - Severe Cardio-pulmonary insufficiency - Diagnosis of Osteonecrosis in the lower limb joints - Pathologies or physical conditions incompatible with the use of magnetic resonance imaging and electrostimulation (i.e., active and passive implanted biomedical devices, epilepsy, severe venous insufficiency in the lower limbs) - Previous interventions or traumas to the joints of the lower limb

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Personalised Musculoskeletal Modeling
Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models

Locations

Country Name City State
Italy IRCCS Istituto Ortopedico Rizzoli Bologna

Sponsors (1)

Lead Sponsor Collaborator
Istituto Ortopedico Rizzoli

Country where clinical trial is conducted

Italy, 

References & Publications (7)

Fernandez J, Zhang J, Heidlauf T, Sartori M, Besier T, Rohrle O, Lloyd D. Multiscale musculoskeletal modelling, data-model fusion and electromyography-informed modelling. Interface Focus. 2016 Apr 6;6(2):20150084. doi: 10.1098/rsfs.2015.0084. — View Citation

Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G. Development of recommendations for SEMG sensors and sensor placement procedures. J Electromyogr Kinesiol. 2000 Oct;10(5):361-74. doi: 10.1016/s1050-6411(00)00027-4. — View Citation

Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012 Jan;67(1):28-40. doi: 10.1093/gerona/glr010. Epub 2011 Mar 28. — View Citation

O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. The effects of agonist and antagonist muscle activation on the knee extension moment-angle relationship in adults and children. Eur J Appl Physiol. 2009 Aug;106(6):849-56. doi: 10.1007/s00421-009-1088-4. Epub 2009 May 27. — View Citation

Petterson SC, Barrance P, Buchanan T, Binder-Macleod S, Snyder-Mackler L. Mechanisms underlying quadriceps weakness in knee osteoarthritis. Med Sci Sports Exerc. 2008 Mar;40(3):422-7. doi: 10.1249/MSS.0b013e31815ef285. — View Citation

Pons C, Borotikar B, Garetier M, Burdin V, Ben Salem D, Lempereur M, Brochard S. Quantifying skeletal muscle volume and shape in humans using MRI: A systematic review of validity and reliability. PLoS One. 2018 Nov 29;13(11):e0207847. doi: 10.1371/journal.pone.0207847. eCollection 2018. — View Citation

Rice DA, McNair PJ. Quadriceps arthrogenic muscle inhibition: neural mechanisms and treatment perspectives. Semin Arthritis Rheum. 2010 Dec;40(3):250-66. doi: 10.1016/j.semarthrit.2009.10.001. Epub 2009 Dec 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle volume Full lower limb MRI data will be acquired with subjects in supine position. Individual muscle volumes (in cm3) will be segmented using commercial software and stored in anonymized form. at baseline (Day 0)
Primary MVIC Torque Dynamometry data will be acquired while participants perform a MVIC leg extension test. The maximum torque values (Nm) measured over three repetitions will be recorded. These correspond to the values observed in correspondence of the plateaux of force, developed over a sustained contraction. at baseline (Day 0)
Primary Muscle Inhibition level The difference between the maximal force exerted during the MVIC test (voluntary contraction) and that achieved when the muscles are electrically stimulated (involuntary contraction) will be computed. at baseline (Day 0)
Primary Co-contraction index (CCI) Experimental EMG data will be recorded from the major lower limb muscles involved in the knee extension, while participants perform a maximal voluntary isometric contraction on a dynamometer (i.e., MVIC test to quantify muscle strength).
The co-contraction index, defined as the relative activation of agonist and antagonist muscles (for this task: quadriceps and hamstrings) in the act of kicking (MVIC test), will be computed according to Li et al (2020).
at baseline (Day 0)
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02905747 - The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis N/A
Completed NCT02901964 - Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial N/A
Completed NCT02881775 - Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis N/A